Rivian shares climb as Q3 revenue beats estimates
Shares of Rivian Automotive RIVN.O rise nearly 3.4% to $12.92 in premarket
Co surpassed third-quarter revenue expectations on Tuesday, fueled by strong deliveries as U.S. consumers rushed to grab a federal tax incentive on electric vehicle purchases before its expiry
TD Cowen maintains a "hold" stance, sees an improving risk/reward profile ahead of co's Autonomous Vehicle/AI event on December 11 and next year's R2 launch
While significant execution risks exist in the coming 12 months and 2026 consensus estimates are by no means "safe," we think near-term risk/reward is starting to skew more favorably into next month's Autonomy/AI Day - TD Cowen
Average rating of 29 analysts is "hold"; median PT $14 - data compiled by LSEG
As of last close, co is down nearly 6% YTD
Related Articles
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemic
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?
The Tariff Refund Drama Begins: Five Major Impacts If Trump Loses the Supreme Court Case
TradingKey - A landmark legal battle with clear undertones of “small business vs. government” will unfold at the U.S. Supreme Court on November 5, a case President Donald Trump has called “the most important in American history.” The ruling will directly determine the legality of Trump’s signature
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.
